Western blotting guide: Part 5, Primary Antibodies

Ideally, the primary antibody should be raised in a different species than the sample to be analyzed. This is to avoid the secondary antibody detecting immunoglobulins from the sample if present. For example, a sample from mouse may contain mouse immunoglobulins. If the primary antibody is also made in mouse, an anti-mouse secondary antibody will detect not only the primary antibody binding to the protein of interest but also to the heavy and light chains of the immunoglobulin in the mouse sample. This can be particularly problematic when the protein of interest has a molecular weight that is similar to either that of the heavy chain (50 kDa) or the light chain (25 kDa), as differentiation between the protein of interest and endogenous mouse IgG becomes impossible.

Both monoclonal and polyclonal antibodies can be used for western blotting. Monoclonal antibodies are produced from a single clone of B cells and produce antibodies specific to one epitope. Whereas polyclonal antibodies are produced from differing B-cell lineages and so contain multiple clones recognizing different epitopes on the antigen. Both types have benefits and limitations (which are shown in the table below).

Table 1. Advantages and disadvantages of Monoclonal and Polyclonal antibodies.

The working solution of the primary antibody is usually made by diluting it using either TBS (Tris-Buffered Saline) or PBS (Phosphate-Buffered Saline). It is essential that the buffer maintains the antibody’s biological activity; therefore, the manufacturer’s recommendations should be followed. Buffers containing detergents (TBS-Tween or PBS-Tween) which are used in washing steps, are also suitable as antibody diluents. As mentioned in Section 4, avoid PBS when detecting phosphorylated proteins because phosphate ions can interfere with the antibody binding.

The concentration of the working antibody solution should be optimized for efficient detection of target protein. Dilute solutions risk not saturating target protein, resulting in low signal. Overly high concentration solutions are not only wasteful but can lead to non-specific bands, high background, or excessive signal intensity.

Each primary antibody must perform as expected, detecting the protein of interest under the experimental conditions. Ideally, suitability for the experiment would be validated for each primary antibody and protein pair for each new experimental set up. Four aspects of primary antibody performance should be addressed during the validation processes. These are:

1. Specificity to the antigen/protein of interest
2. Specificity to the antigen under experimental conditions (native or denatured)
3. Affinity for the antigen
4. Reproducibility

Specificity to the antigen/protein of interest

Use negative and positive controls to establish that a primary antibody is specific to the protein of interest, ideally using purified and/or control material. It is important to include a blank sample or negative sample control to establish if the primary antibody detects endogenous proteins.

Specificity to the antigen under experimental conditions (native or denatured)

It is important to establish if a primary antibody is suitable for the detection of the target protein under the experimental conditions. This may be because a primary antibody that is suitable for use in IHC, where antigens are in their native forms, may not be able to detect the linearised antigens of proteins in western blotting and vice versa.

Affinity for the antigen

Although a primary antibody may detect the protein of interest specifically or across a range of techniques, it may not have sufficient affinity to produce a signal brighter than background.

One of the problems that can be encountered with primary antibodies is the difficulty in replicating results. This may be because of batch to batch variability or poorly characterized specificity.

A recent movement in life-science research has been to encourage manufacturers to validate their antibodies and confirm detection of stated target antigens in specific applications. In an effort to improve and promote research resource identification, discovery, and reuse, the Resource Identification Portal was created in support of the Resource Identification Initiative. Research Resource Identifiers (RRIDs) are assigned to research materials and are unique identifiers allowing researchers to trace materials.

Specific to antibodies, the Antibody Registry catalogs antibody RRIDs to clarify their use in published literature.

Ideally, a researcher should confirm the product performs reliably, preferably using a positive control in the technique desired.

Positive control

Most primary antibodies are available with a positive control from purified protein. These controls can be run in parallel with the sample and the migration of the protein compared to the bands detected from the sample.

Tissue controls

If possible, a positive tissue control is used to determine antibody specificity and performance in detecting processed proteins. The specificity of the antibody is confirmed using cells or tissue samples known to express the protein of interest. A band observed at the expected weight provides a positive indication of antibody specificity. A negative tissue control is useful to determine non-specificity of the primary antibody. A sample of tissues or cells known not to express the target protein is probed with the primary antibody. An absence of bands is desired; any non-specific detection of proteins in the sample can indicate detection of endogenous proteins.

Negative or secondary antibody control

A secondary antibody control is simply the probing of the membrane without the primary antibody. This can be used to confirm if blocking/washing of membrane has been adequate and identify any background signal generated by the secondary antibody.

1. Blancher C. et al. (2001). SDS-PAGE and Western Blotting Techniques. Methods in Molecular Medicine. doi: 10.1385/1-59259- 136-1:145.
2. Jackson ImmunoResearch Laboratories Inc. (2017). Western Blotting Troubleshooting Guide! https://www.jacksonimmuno.com/secondary-antibody-resource/technical-tips/western-blot-trouble-shooting/
3. GE Healthcare. (2011). Western Blotting Principles and Methods. https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma-Aldrich/General_Information/1/ge-western-blotting.pdf
4. Bass J.J. et al. (2017). An Overview of Technical Considerations for Western Blotting Applications to Physiological Research. Scandinavian Journal of Medicine and Science in Sports. doi: 10.1111/sms.12702
5. Lewis M. (2018). A Guide to Selecting Control and Blocking Reagents. Jackson ImmunoResearch Laboratories Inc. https://www.jacksonimmuno.com/secondary-antibody-resource/technical-tips/controls-diluents-blocking/
6. Kelly M.F. et al. (2016). Antibody Validation. Mater Methods. doi.org/10.13070/mm.en.6.1540
7. Lewis M. (2018). Cross-Adsorbed Secondary Antibodies and Cross-Reactivity. Jackson ImmunoResearch Laboratories Inc.https://www.jacksonimmuno.com/secondary-antibody-resource/technical-tips/cross-adsorbed-and-cross-reactivity/
8. Baker M (2015) Reproducibility crisis: Blame it on the antibodies Nature. 19th May 2015
9. Bradbury & Plückthun (2015) Reproducibility: Standardize antibodies used in research. Nature. 04 February 2015
10. Bordeaux et al. (2010) Antibody validation Biotechniques. 2010 Mar; 48(3): 197–209.
11. EMBO meeting 2016: Lex Bouter, The replicability crisis.